Delving into the Latest Updates on The Beijing Pregene Science and Technology Company, Ltd. with Synapse

概览

关联

1

项与 The Beijing Pregene Science and Technology Company, Ltd. 相关的药物

Anti CD19 CAR-T (Beijing Pregene )

靶点

CD19

作用机制

CD19抑制剂 [+2]

在研机构-

原研机构

The Beijing Pregene Science and Technology Company, Ltd.

在研适应症-

非在研适应症

CD19阳性B细胞急性淋巴细胞白血病 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

4

项与 The Beijing Pregene Science and Technology Company, Ltd. 相关的临床试验

NCT03152435 / Unknown status临床1/2期IIT

Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.

开始日期2017-06-15

申办/合作机构

深圳市第二人民医院

[+1]

NCT03146533 / Unknown status临床1/2期IIT

Phase I/II Study of CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory patients with CD19+ B cell lymphoma.

开始日期2017-05-01

申办/合作机构

深圳市第二人民医院

[+1]

NCT03101709 / Unknown status临床1期IIT

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.

开始日期2016-08-01

申办/合作机构